Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":104456603,"tweetId":"104456603","gmtCreate":1620406807902,"gmtModify":1634205443385,"author":{"id":3559742442220848,"idStr":"3559742442220848","authorId":3559742442220848,"authorIdStr":"3559742442220848","name":"Naaaiiviv","avatar":"https://static.tigerbbs.com/f960362e5c51023817630505ca72c17e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Like&nbsp;</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/104456603","repostId":2133688507,"repostType":4,"repost":{"id":"2133688507","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1620398076,"share":"https://www.laohu8.com/m/news/2133688507?lang=zh_CN&edition=full","pubTime":"2021-05-07 22:34","market":"us","language":"en","title":"Pfizer, BioNTech Seek Full FDA Approval For Covid Vaccine; Shares Pop<blockquote>辉瑞、BioNTech寻求FDA全面批准Covid疫苗；股票流行</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2133688507","media":"Investors","summary":"Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop. That followed patent questions that hurt shares.","content":"<p><b>Pfizer</b> and <b>BioNTech</b> asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop.</p><p><blockquote><b>辉瑞</b>和<b>BioNTech</b>周五要求食品和药物管理局全面批准其新冠疫苗，导致BioNTech股价上涨。</blockquote></p><p>The vaccine is already authorized for emergency use in people ages 16 and older. But if approved, the vaccine could stay on the market after the pandemic ends. The companies could also market directly to consumers and change the price.</p><p><blockquote>该疫苗已被授权在16岁及以上人群中紧急使用。但如果获得批准，该疫苗可能会在大流行结束后继续上市。这些公司还可以直接向消费者营销并改变价格。</blockquote></p><p>\"Following the successful delivery of more than 170 million doses to the U.S. population in just a few months, the (application) submission is an important cornerstone of achieving long-term herd immunity and containing Covid-19 in the future,\" BioNTech Chief Executive Ugur Sahin said in a written statement.</p><p><blockquote>BioNTech首席执行官表示：“在短短几个月内成功向美国人口提供了超过1.7亿剂疫苗后，（申请）提交是实现长期群体免疫和未来遏制Covid-19的重要基石。”Ugur Sahin在一份书面声明中表示。</blockquote></p><p>In morning trading on today's stock market, BioNTech stock jumped 5.6% near 177.40. Pfizer stock rose 0.9% near 39.60.</p><p><blockquote>在今天股市早盘交易中，BioNTech股价上涨5.6%，接近177.40点。辉瑞股价上涨0.9%，接近39.60点。</blockquote></p><p><h2>BioNTech Stock Pops On FDA Submission</h2>Pfizer and BioNTech gained emergency authorization for their Covid vaccine in December. At that time, the FDA said it would require at least six months of follow-up data in vaccinated volunteers before considering a full approval.</p><p><blockquote><h2>BioNTech股票因FDA提交而上涨</h2>辉瑞和BioNTech于12月获得了新冠疫苗的紧急授权。当时，FDA表示，在考虑全面批准之前，需要在接种疫苗的志愿者中进行至少6个月的随访数据。</blockquote></p><p>The data submitted Friday to the FDA include the most recent analysis from Phase 3 testing. The companies' observed the vaccine's safety and effectiveness for up to six months after the second dose, Pfizer and BioNTech said in a news release.</p><p><blockquote>周五提交给FDA的数据包括3期测试的最新分析。辉瑞和BioNTech在一份新闻稿中表示，两家公司在第二剂疫苗接种后长达六个月的时间里观察了疫苗的安全性和有效性。</blockquote></p><p>\"We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months,\" Pfizer Chief Executive Albert Bourla said in a written statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla在一份书面声明中表示：“我们期待与FDA合作，完成这一滚动提交并支持他们的审查，目标是在未来几个月内获得该疫苗的全面监管批准。”</blockquote></p><p>Next, the FDA must decide whether the accept or reject the application. Then, the agency will set a date to review it. That could also stoke BioNTech stock.</p><p><blockquote>接下来，FDA必须决定是接受还是拒绝该申请。然后，该机构将确定一个日期进行审查。这也可能提振BioNTech股票。</blockquote></p><p><h2>Vaccine Shares Recover</h2>The news Friday was a breath of fresh air for BioNTech stock.</p><p><blockquote><h2>疫苗股回升</h2>周五的消息对BioNTech股票来说是一股新鲜空气。</blockquote></p><p>Earlier this week, shares were under pressure after President Joe Biden and his administration voiced support for waiving patent rights for Covid vaccines. The goal is to help other countries make their own vaccines. BioNTech stock lost nearly 20% this week, as of Thursday's close.</p><p><blockquote>本周早些时候，在总统乔·拜登及其政府表示支持放弃新冠疫苗专利权后，股价承压。目标是帮助其他国家制造自己的疫苗。截至周四收盘，BioNTech股价本周下跌近20%。</blockquote></p><p>On Thursday, though, German Chancellor Angela Merkel opposed waiving patent protection for vaccines. That helped BioNTech, which is based in Mainz, Germany, pare much deeper losses. At <a href=\"https://laohu8.com/S/AONE\">one</a> point, BioNTech stock was off by 15%.</p><p><blockquote>不过，周四，德国总理安格拉·默克尔反对放弃疫苗专利保护。这帮助总部位于德国美因茨的BioNTech削减了更大的亏损。在<a href=\"https://laohu8.com/S/AONE\">一</a>BioNTech股价下跌15%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech Seek Full FDA Approval For Covid Vaccine; Shares Pop<blockquote>辉瑞、BioNTech寻求FDA全面批准Covid疫苗；股票流行</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech Seek Full FDA Approval For Covid Vaccine; Shares Pop<blockquote>辉瑞、BioNTech寻求FDA全面批准Covid疫苗；股票流行</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-05-07 22:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer</b> and <b>BioNTech</b> asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop.</p><p><blockquote><b>辉瑞</b>和<b>BioNTech</b>周五要求食品和药物管理局全面批准其新冠疫苗，导致BioNTech股价上涨。</blockquote></p><p>The vaccine is already authorized for emergency use in people ages 16 and older. But if approved, the vaccine could stay on the market after the pandemic ends. The companies could also market directly to consumers and change the price.</p><p><blockquote>该疫苗已被授权在16岁及以上人群中紧急使用。但如果获得批准，该疫苗可能会在大流行结束后继续上市。这些公司还可以直接向消费者营销并改变价格。</blockquote></p><p>\"Following the successful delivery of more than 170 million doses to the U.S. population in just a few months, the (application) submission is an important cornerstone of achieving long-term herd immunity and containing Covid-19 in the future,\" BioNTech Chief Executive Ugur Sahin said in a written statement.</p><p><blockquote>BioNTech首席执行官表示：“在短短几个月内成功向美国人口提供了超过1.7亿剂疫苗后，（申请）提交是实现长期群体免疫和未来遏制Covid-19的重要基石。”Ugur Sahin在一份书面声明中表示。</blockquote></p><p>In morning trading on today's stock market, BioNTech stock jumped 5.6% near 177.40. Pfizer stock rose 0.9% near 39.60.</p><p><blockquote>在今天股市早盘交易中，BioNTech股价上涨5.6%，接近177.40点。辉瑞股价上涨0.9%，接近39.60点。</blockquote></p><p><h2>BioNTech Stock Pops On FDA Submission</h2>Pfizer and BioNTech gained emergency authorization for their Covid vaccine in December. At that time, the FDA said it would require at least six months of follow-up data in vaccinated volunteers before considering a full approval.</p><p><blockquote><h2>BioNTech股票因FDA提交而上涨</h2>辉瑞和BioNTech于12月获得了新冠疫苗的紧急授权。当时，FDA表示，在考虑全面批准之前，需要在接种疫苗的志愿者中进行至少6个月的随访数据。</blockquote></p><p>The data submitted Friday to the FDA include the most recent analysis from Phase 3 testing. The companies' observed the vaccine's safety and effectiveness for up to six months after the second dose, Pfizer and BioNTech said in a news release.</p><p><blockquote>周五提交给FDA的数据包括3期测试的最新分析。辉瑞和BioNTech在一份新闻稿中表示，两家公司在第二剂疫苗接种后长达六个月的时间里观察了疫苗的安全性和有效性。</blockquote></p><p>\"We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months,\" Pfizer Chief Executive Albert Bourla said in a written statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla在一份书面声明中表示：“我们期待与FDA合作，完成这一滚动提交并支持他们的审查，目标是在未来几个月内获得该疫苗的全面监管批准。”</blockquote></p><p>Next, the FDA must decide whether the accept or reject the application. Then, the agency will set a date to review it. That could also stoke BioNTech stock.</p><p><blockquote>接下来，FDA必须决定是接受还是拒绝该申请。然后，该机构将确定一个日期进行审查。这也可能提振BioNTech股票。</blockquote></p><p><h2>Vaccine Shares Recover</h2>The news Friday was a breath of fresh air for BioNTech stock.</p><p><blockquote><h2>疫苗股回升</h2>周五的消息对BioNTech股票来说是一股新鲜空气。</blockquote></p><p>Earlier this week, shares were under pressure after President Joe Biden and his administration voiced support for waiving patent rights for Covid vaccines. The goal is to help other countries make their own vaccines. BioNTech stock lost nearly 20% this week, as of Thursday's close.</p><p><blockquote>本周早些时候，在总统乔·拜登及其政府表示支持放弃新冠疫苗专利权后，股价承压。目标是帮助其他国家制造自己的疫苗。截至周四收盘，BioNTech股价本周下跌近20%。</blockquote></p><p>On Thursday, though, German Chancellor Angela Merkel opposed waiving patent protection for vaccines. That helped BioNTech, which is based in Mainz, Germany, pare much deeper losses. At <a href=\"https://laohu8.com/S/AONE\">one</a> point, BioNTech stock was off by 15%.</p><p><blockquote>不过，周四，德国总理安格拉·默克尔反对放弃疫苗专利保护。这帮助总部位于德国美因茨的BioNTech削减了更大的亏损。在<a href=\"https://laohu8.com/S/AONE\">一</a>BioNTech股价下跌15%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2133688507","content_text":"Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop.The vaccine is already authorized for emergency use in people ages 16 and older. But if approved, the vaccine could stay on the market after the pandemic ends. The companies could also market directly to consumers and change the price.\"Following the successful delivery of more than 170 million doses to the U.S. population in just a few months, the (application) submission is an important cornerstone of achieving long-term herd immunity and containing Covid-19 in the future,\" BioNTech Chief Executive Ugur Sahin said in a written statement.In morning trading on today's stock market, BioNTech stock jumped 5.6% near 177.40. Pfizer stock rose 0.9% near 39.60.BioNTech Stock Pops On FDA SubmissionPfizer and BioNTech gained emergency authorization for their Covid vaccine in December. At that time, the FDA said it would require at least six months of follow-up data in vaccinated volunteers before considering a full approval.The data submitted Friday to the FDA include the most recent analysis from Phase 3 testing. The companies' observed the vaccine's safety and effectiveness for up to six months after the second dose, Pfizer and BioNTech said in a news release.\"We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months,\" Pfizer Chief Executive Albert Bourla said in a written statement.Next, the FDA must decide whether the accept or reject the application. Then, the agency will set a date to review it. That could also stoke BioNTech stock.Vaccine Shares RecoverThe news Friday was a breath of fresh air for BioNTech stock.Earlier this week, shares were under pressure after President Joe Biden and his administration voiced support for waiving patent rights for Covid vaccines. The goal is to help other countries make their own vaccines. BioNTech stock lost nearly 20% this week, as of Thursday's close.On Thursday, though, German Chancellor Angela Merkel opposed waiving patent protection for vaccines. That helped BioNTech, which is based in Mainz, Germany, pare much deeper losses. At one point, BioNTech stock was off by 15%.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":488,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/104456603"}